Cost-Effective Alternative to Synjardy
The most cost-effective substitute for Synjardy (empagliflozin/metformin) is metformin plus a sulfonylurea, which provides the best value at approximately $12,757 per QALY gained compared to metformin alone 1, 2.
Rationale Based on Cost-Effectiveness Evidence
The 2024 American College of Physicians systematic review definitively establishes that SGLT2 inhibitors like empagliflozin are "low value" as first-line or second-line therapy when compared to older agents 1. The evidence shows:
- Sulfonylureas added to metformin represent the most cost-effective second-line option at $12,757/QALY 2
- SGLT2 inhibitors (including empagliflozin) cost >$150,000 per QALY when used as first-line therapy—classified as "low value" with high certainty of evidence 1
- SGLT2 inhibitors only achieve "intermediate value" ($50,000-$150,000/QALY) when added to metformin in patients who have failed other therapies 1
Specific Replacement Strategy
Replace Synjardy with:
- Metformin (same dose as in Synjardy) + Sulfonylurea (e.g., glipizide, glyburide, or glimepiride)
- This combination costs dramatically less while providing comparable glycemic control
- Sulfonylureas are available as generics at minimal cost
Important Clinical Considerations
When This Substitution May NOT Be Appropriate
You should maintain empagliflozin (consider switching to separate empagliflozin + generic metformin rather than branded Synjardy) if the patient has:
- Established cardiovascular disease 3
- Heart failure (empagliflozin reduces CV death and hospitalization) 3
- Chronic kidney disease at risk of progression (empagliflozin reduces eGFR decline and ESRD) 3
In these specific populations, empagliflozin provides mortality and morbidity benefits beyond glucose control that justify its cost 4, 5.
Safety Trade-offs with Sulfonylureas
- Hypoglycemia risk: Higher with sulfonylureas than SGLT2 inhibitors—requires patient education and glucose monitoring
- Weight: Sulfonylureas may cause modest weight gain vs. weight loss with empagliflozin
- No cardiovascular benefit: Unlike empagliflozin, sulfonylureas don't reduce CV events
Alternative Cost-Saving Strategy
If the patient is currently on branded Synjardy, consider:
- Generic empagliflozin + generic metformin separately (if empagliflozin is indicated for CV/renal protection)
- This maintains therapeutic benefit while reducing cost compared to the branded combination product
Bottom Line
For pure glycemic control without cardiovascular or renal complications, metformin plus sulfonylurea is the evidence-based, cost-effective alternative 1, 2. The 2024 ACP guidelines with high certainty of evidence confirm that SGLT2 inhibitors like empagliflozin are not cost-effective for routine diabetes management when older, proven therapies remain available 1.